Compare iShares MSCI Hong Kong ETF (EWH) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Hong Kong ETF vs Novavax Inc — how do they compare? iShares MSCI Hong Kong ETF trades at $22.07 (market cap $1.16B), while Novavax Inc trades at $12.04 (market cap $1.82B). The key difference: Novavax Inc is the larger of the two by market cap, and Novavax Inc is trading nearer its 52-week high, iShares MSCI Hong Kong ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Hong Kong ETF for 61 Days and Novavax Inc for 59 Days on average.
| EWH | NVAX | |
|---|---|---|
Market Cap | $1.16B | $1.82B |
Volume | 3,176,523 | 6,198,505 |
Sector | Broad Market / Factor | Health |
52-Week High | $24.55 | $12.56 |
52-Week Low | $20.66 | $6.22 |
Typical Hold Time | 61 Days | 59 Days |
Enterprise Value | — | $1.39B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWH, the iShares MSCI Hong Kong ETF, trades at $22.04, up 2.13% in the last 24 hours. The technical outlook is bearish, with moving averages signaling a downtrend and key support at $21. Recent news highlights volatility in the Hang Seng Index, driven by Federal Reserve decisions and geopolitical tensions. Financial ratios are unavailable in the provided data, limiting fundamental assessment.
The ETF faces headwinds from Hong Kong market weakness and institutional selling, but oversold conditions per RSI may offer tactical opportunities. Risks include ongoing U.S.-China tensions and economic pressures. Investors should weigh exposure to Hong Kong equities against broader market risks.
Novavax (NVAX) trades at $11.22, down 0.88% on the day, with a bullish technical signal from moving averages and a neutral RSI. The company reported strong revenue of $1.12 billion in 2025 and a net income of $440.30 million, but faces negative cash flow and a projected net loss for 2026. Recent news highlights its strategic pivot to a partnership-driven model using its Matrix-M adjuvant technology, with regulatory approvals for its updated COVID-19 vaccine in key markets.
The outlook for NVAX is mixed, with analyst consensus strongly favoring a buy rating (73.92%) but significant financial risks including negative equity, persistent cash burn, and volatile earnings. Investment opportunity lies in the successful execution of its licensing strategy and expansion into oncology, though execution risks and competitive pressures remain key concerns for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI Hong Kong ETF
EWH tracks the MSCI Hong Kong 25/50 Index, providing broad exposure to large and mid-cap companies listed in Hong Kong. It focuses on the established pillars of the local economy, with heavy weightings in financials, real estate, and utilities, serving as a single-country diversification tool.
Read more on EWH →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
